Table 2.
Baseline characteristics of included studies.
| Author, year | Cases |
Male% |
Age |
Diabetes mellitus% |
Hypertension% |
Device type | Inflation time | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PCB | CB | PCB | CB | PCB | CB | PCB | CB | PCB | CB | |||
| Arabi, 2021 [17] | 12 | 11 | 41.7 | 54.5 | 68.7 ± 10.1 | 66.8 ± 13.7 | 91.7 | 72.7 | 100 | 90.9 | PCB: Lutonix 035, Bard (2 µg/mm2) Control: unspecified |
120 sec |
| Björkman, 2019 [21] | 21 | 18 | 55.6 | 72.2 | 67.4 (46–87) | 67.0 (28–82) | 61.1 | 61.1 | 88.9 | 77.8 | PCB: IN. PACT Admiral, Medtronic (3.5 µg/mm2) Control: unspecified |
90 sec |
| Karmota, 2020 [8] | 30 | 30 | 43.3 | 53.3 | 54.7 ± 13.2 | 49.2 ± 11.5 | 63.3 | 50.0 | 50.0 | 56.7 | PCB: Lutonix 035, Bard (dose unspecified) Control: unspecified |
180 sec |
| Karunanithy, 2021 [18] | 106 | 106 | 63.2 | 57.5 | 66.9 ± 12.7 | 64.1 ± 13.3 | 54.7 | 43.4 | – | – | PCB: Lutonix 035, Bard (2 µg/mm2) Control: Ultraverse, Bard |
Unspecified |
| Kim, 2020 [19] | 20 | 19 | 60.0 | 47.4 | 60.7 ± 12.2 | 63.7 ± 11.8 | 80.0 | 78.9 | – | – | PCB: IN. PACT Admiral, Medtronic (dose unspecified) CB: Mustang, Boston Scientific |
120 sec |
| Kitrou, EJR, 2015-AVF [9] | 7 | 7 | 75 | 70 | 65.7 ± 13.2 | 62.5 ± 15.4 | 20 | 20 | 15 | 10 | PCB: IN. PACT Admiral, Medtronic (3 µg/mm2) Control: HPB |
Unspecified |
| Kitrou, JVIR, 2015 [10] | 20 | 20 | 60 | 70 | 64.3 ± 14.5 | 57 ± 14.2 | 20 | 35 | 15 | 15 | PCB: IN. PACT Admiral, Medtronic (3 µg/mm2) Control: HPB |
90 sec |
| Lai, 2014 [11] | 10 | 10 | 40 | 67.2 ± 9.4 | 50 | 40 | PCB: SeQuent Please, B.Braun (dose unspecified) CB: unspecified |
60 sec | ||||
| Lookstein, 2020 [12] | 170 | 160 | 65.9 | 63.1 | 65.8 ± 13.1 | 65.5 ± 13.4 | 62.9 | 68.8 | 91.2 | 94.4 | PCB: IN. PACT Admiral, Medtronic (3.5 µg/mm2) Control: uncoated balloon |
Unspecified |
| Maleux, 2018 [20] | 33 | 31 | 72.7 | 58.1 | 69.3 ± 14.9 | 66.9 ± 17 | – | – | – | – | PCB: IN. PACT Admiral, Invatec/Medtronic (dose unspecified) Control: Admiral Extreme, Invatec/Medtronic |
Unspecified |
| Swinnen, 2018 [13] | 68 | 60 | 61.8 | 61.7 | 65.2 ± 13.6 | 64.5 ± 13.9 | 55.9 | 65.0 | – | – | PCB: IN. PACT Admiral/Pacific, Medtronic (3 µg/mm2) Control: uncoated angioplasty balloon of the operator’s choice |
120 sec |
| Therasse, 2021-AVF [14] | 60 | 60 | 83.3 | 83.3 | 63.5 ± 12.6 | 66.6 ± 12.6 | 61.7 | 71.7 | 86.7 | 81.7 | PCB: Passeo-18 Lux, Biotronik (3 µg/mm2) CB: same type without drug |
60 sec |
| Trerotola, 2020 [15] | 141 | 144 | 61.7 | 59 | 64 ± 15 | 61 ± 13 | 58.2 | 65.3 | 94.3 | 98.6 | PCB: Lutonix 035, Bard (2 µg/mm2) Control: control balloon of similar design but without drug coating |
Unspecified |
| Yin, 2021 [16] | 78 | 83 | 56.4 | 50.6 | 56 ± 13 | 54 ± 13 | 34.6 | 34.9 | 84.6 | 84.3 | PCB: APERTO, Cardionovum (3 µg/mm2) Control: Ohicho II HPBs, Kaneka Corp |
120–180 sec |
PCB: paclitaxel coated balloon; CB: conventional balloon; sec: seconds; -: missing data.